The option offers a quicker, cheaper alternative, preferred by patients and involving less exposure to radiation.
News
R&D SMEs at risk due to tax credit scheme change
The aim is to prevent fraud, but analysis by the BIA shows the measure will have unintended consequences for life science companies.
UK should be “proud” of service and supply sector
Service and supply companies account for 80% of small and medium enterprises (SMEs) in UK medicines discovery, and 90% of employment.
SMC approves new cancer drugs, among others
Drugs for breast cancer, skin cancer and schizophrenia have been approved.
Closed Loop secures £2.1m funding
The funding will support the development of a drug and digital approach to treat and manage major health conditions.
NHS to tackle elderly over-medication with 200 new pharmacists
The recruits are part of a wider £20 million programme to reduce unnecessary medication of patients.
NIHR launches new interactive costing tool
The tool aims to enable faster costing and contracting between the life sciences industry and the NHS.
AZ, Forty Seven to test triple immunotherapy combo for lymphoma
5F9 will be tested in combination with rituximab and Calquence (acalabrutinib) for diffuse large B-cell lymphoma.
‘Groundbreaking’ new brain cancer treatment available
The treatment is a part of the NHS Long Term Plan, which aims to save thousands more lives by catching more cancers early and starting treatment fast.
£2m NHS investment into leadership development
The programme fits in with the NHS Long Term Plan, as it sets out to “nurture the next generation of NHS leaders”.
Potential first ever targeted therapy designed for ‘untreatable’ childhood brain cancer
The new drug class can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice.
Sanofi granted EU licensing for Dupixent
The approval marks the first biologic licensed in the EU for severe asthma with type II inflammation.
World Lupus Day: new report reveals need for care improvements
Lupus affects 5 million patients worldwide, predominantly female.
New report reveals priorities for local NHS research and innovation
Mental health and complex health issues among common themes that emerged from the consultation
Gilead, Goldfinch to team up against kidney disease
The multi-year collaboration will expand the scope of Goldfinch’s proprietary Kidney Genome Atlas.
